You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科濟藥業(02171.HK)治療骨髓瘤注射液臨床試驗展現有前景療效
阿思達克 09-21 08:32
科濟藥業-B(02171.HK)公布,在馬薩諸塞州波士頓舉行的第七屆CAR-TCR年度峰會上,公司口頭介紹澤沃基奧侖賽注射液(zevor-cel,產品編號:CT053)(一種針對BCMA的自體CAR-T候選產品)北美2期臨床試驗。 該項多中心、開放標籤的1b/2期試驗(NCT03915184)正在進行以評估在北美復發/難治多發性骨髓瘤(R/R MM)患者中的安全性和有效性。 zevor-cel在2期試驗初始的17名復發/難治多發性骨髓瘤,採用1.8×10 CAR-T細胞劑量治療的患者中展現出有前景的療效以及微小殘留病變(MRD)陰性。門診治療目前正在探索之中。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account